Atea Pharmaceuticals (AVIR) Return on Capital Employed (2020 - 2026)
Atea Pharmaceuticals' (AVIR) quarterly Return on Capital Employed came in at 73.65% in Q1 2026, down 3598.0% year-on-year from 2.11% in Q1 2025, and down 17.79% quarter-over-quarter from 62.52% in Q4 2025.
Atea Pharmaceuticals (AVIR) Return on Capital Employed (2020 - 2026) Analysis & Trends
Atea Pharmaceuticals' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 73.65% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 3598.0% year-over-year to 73.65% in Q1 2026; TTM through Mar 2026 was 73.65%, a 3598.0% decrease from a year earlier, with the FY2025 full-year figure at 51.66%, down 1392.0% from the prior year.
- Return on Capital Employed retreated to 73.65% in Q1 2026 per AVIR's latest filing, from 62.52% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 9.15% in Q1 2022 and bottomed at 73.65% in Q1 2026.
- The 5-year median for Return on Capital Employed is 36.12% (2024), against an average of 30.67%.
- Biggest YoY gain for Return on Capital Employed was 519 bps in 2022; the steepest drop was 3827 bps in 2022.
- Year by year, Return on Capital Employed stood at 19.85% in 2022, then plunged by 45 bps to 28.84% in 2023, then slumped by 46 bps to 42.02% in 2024, then plunged by 49 bps to 62.52% in 2025, then dropped by 18 bps to 73.65% in 2026.
- Per Business Quant, the three latest AVIR Return on Capital Employed figures stand at 73.65% (Q1 2026), 62.52% (Q4 2025), and 47.53% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Atea Pharmaceuticals | 376.19 Mn | 376.19 Mn | - | -73.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.65% |
| Dec 31, 2025 | -62.52% |
| Sep 30, 2025 | -47.53% |
| Jun 30, 2025 | -39.58% |
| Mar 31, 2025 | -37.67% |
| Dec 31, 2024 | -42.02% |
| Sep 30, 2024 | -42.17% |
| Jun 30, 2024 | -40.40% |
| Mar 31, 2024 | -36.12% |
| Dec 31, 2023 | -28.84% |
| Sep 30, 2023 | -26.33% |
| Jun 30, 2023 | -21.59% |
| Mar 31, 2023 | -20.32% |
| Dec 31, 2022 | -19.85% |
| Sep 30, 2022 | 4.51% |
| Jun 30, 2022 | 3.61% |
| Mar 31, 2022 | 9.15% |
| Dec 31, 2021 | 18.42% |
| Sep 30, 2021 | 6.35% |
| Jun 30, 2021 | 7.27% |